1 |
Genetics of breast cancer for the practicing surgeon. Agashe PP, Shrikhande SV. http://www.bhj.org/journal/2001_4304_oct/review_537.htm. Accessed June 12th, 2011.
|
2 |
Types of breast cancer: ER positive, HER2 positive, and triple negative. WebMD. http://www.webmd.com/breast-cancer/breast-cancer-typeser- positive-her2-positive. Accessed August 2nd, 2010.
|
3 |
Breast cancer: tumor biology. Winship Cancer Institute. http://www. cancerquest.org/breast-cancer-molecular-biology. Accessed August 4th, 2010.
|
4 |
Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 2002;87: 805-12.
DOI
|
5 |
Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53:116-22.
DOI
|
6 |
Sinthupibulyakit C, Grimes KR, Domann FE, Xu Y, Fang F, Ittarat W, et al. p53 is an important factor for the radiosensitization effect of 2-deoxy- D-glucose. Int J Oncol 2009;35:609-15.
|
7 |
Ahmad IM, Mustafa EH, Mustafa NH, Tahtamouni LH, Abdalla MY. 2DG enhances the susceptibility of breast cancer cells to doxorubicin. Cent Eur J Biol 2010;5:739-48.
|
8 |
Zhang F, Aft RL. Chemosensitizing and cytotoxic effects of 2-deoxy-Dglucose on breast cancer cells. J Cancer Res Ther 2009;5 Suppl 1:S41-3.
|
9 |
Kalia VK, Prabhakara S, Narayanan V. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. J Cancer Res Ther 2009;5 Suppl 1:S57-60.
DOI
|
10 |
Dwarakanath BS. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther 2009;5 Suppl 1:S27-31.
DOI
|
11 |
Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation- induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci 2000;899:349-62.
|
12 |
Han W, Kang SY; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010;119:193-200.
DOI
|
13 |
Rodeh HJ, Eisel D, Frost I. Apoptosis, Cell Death and Cell Proliferation. 3rd ed. Mannheim: Roche Diagnostics GmbH; 2000. p.2-6.
|
14 |
Cobb JP, Hotchkiss RS, Karl IE, Buchman TG. Mechanisms of cell injury and death. Br J Anaesth 1996;77:3-10.
DOI
|
15 |
Ghilotti M, Pierotti MA, Gariboldi M. Molecular markers for prediction of risk of radiation-related injury to normal tissue. J Nucleic Acids Investig 2010;1:55-61.
|
16 |
Dwarkanath BS, Zolzer F, Chandana S, Bauch T, Adhikari JS, Muller WU, et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001;50:1051-61.
DOI
|
17 |
Schwarz SB, Schaffer PM, Kulka U, Ertl-Wagner B, Hell R, Schaffer M. The effect of radio-adaptive doses on HT29 and GM637 cells. Radiat Oncol 2008;3:12.
DOI
|
18 |
Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996;35:103-11.
|
19 |
Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase- 9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008; 14:3617-26.
DOI
|
20 |
Gupta S, Farooque A, Adhikari JS, Singh S, Dwarakanath BS. Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy- D-glucose in animal tumors. J Cancer Res Ther 2009;5 Suppl 1:S16-20.
DOI
|
21 |
Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
DOI
|
22 |
Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002;74:155-65.
DOI
|
23 |
Kaabinejadian S, Fouladdel SH, Ramezani M, Azizi E. p53 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. J Biol Sci 2008; 8:380-5.
DOI
|
24 |
de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
DOI
|
25 |
Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009; 418:29-37.
DOI
|
26 |
Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
DOI
|
27 |
Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174-81.
DOI
|
28 |
Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy- D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67:3364-70.
DOI
|
29 |
Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. Effects of 2-deoxy- D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985;11:943-50.
DOI
|
30 |
Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 1998;76:22-6.
DOI
|
31 |
Ahmad IM, Abdalla MY, Aykin-Burns N, Simons AL, Oberley LW, Domann FE, et al. 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. Free Radic Biol Med 2008;44:826-34.
DOI
|
32 |
Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol 1999;180:431-8.
DOI
|
33 |
Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011;71:4585-97.
DOI
|